Eli Lilly Acquires Centessa for $6.3B to Bolster Neuroscience Pipeline with Sleep Disorder Drugs
Eli Lilly has announced a $6.3 billion acquisition of Centessa Pharmaceuticals, securing two sleep disorder drugs that fill a critical gap in Lilly's neuroscience portfolio.
The Deal
- Target: Centessa Pharmaceuticals
- Value: $6.3 billion
- Key assets: Two sleep disorder drugs (narcolepsy and related conditions)
- Strategic fit: Fills neuroscience pipeline hole
- Competition: Intensifies rivalry with Takeda and Eisai
Why Sleep Disorders?
Sleep medicine represents a massive and growing market:
- Narcolepsy: Affects ~1 in 2,000 people, with current treatments having significant limitations
- Insomnia: Affects ~30% of adults, massive unmet need
- Market: Sleep disorder therapeutics market projected to exceed $30B by 2030
Lilly's Neuroscience Push
Lilly has been aggressively expanding its neuroscience portfolio beyond its core metabolic (GLP-1) franchise. The Centessa acquisition follows a broader industry trend of pharma giants acquiring neuroscience assets as the pipeline for brain drugs has been historically thin.
Deal Structure
Both the Lilly-Centessa and Biogen-Apellis deals use Contingent Value Rights (CVRs) — a voucher-like security experiencing renewed popularity as a mechanism to bridge valuation gaps between buyers and sellers.
CVRs provide sellers with additional future payments if specific milestones are achieved, reducing upfront risk for acquirers while preserving upside for sellers.